Previous Article | Next Article ![]()
Molecular and Cellular Biology, June 2007, p. 4105-4120, Vol. 27, No. 11
0270-7306/07/$08.00+0 doi:10.1128/MCB.00248-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Min Luo,2,
Mingshi Koh,2,
Meng Yang,2
Mohammed Nizam bin Abdul Kadir,2
Jing Hui Tan,2
Zhiyong Ye,2
Wen Wang,2 and
Philippa Melamed2*
National University of Singapore, Graduate School for Integrative Sciences and Engineering, Centre for Life Sciences, 05-01 28 Medical Drive, Singapore 117456, Republic of Singapore,1 Department of Biological Sciences, National University of Singapore, 14 Science Drive 4, Singapore 117542, Republic of Singapore2
Received 11 February 2007/ Accepted 9 March 2007
|
|
|---|
|
|
|---|
-subunit is first expressed, and E16.5 when the luteinizing hormone ß-subunit (LHß) gene is first detected, while expression of the follicle-stimulating hormone ß-subunit (FSHß) gene appears on the following day. The expression of these genes is facilitated by unique cell-specific groups of transcription factors which are expressed in response to local signals, and most are present by E9 to 13.5 (6, 23, 50). Expression of these transcription factors (e.g., SF-1, Egr-1, and Pitx-1 for LH and SF-1, AP-1, Lhx3, Ptx1, and Ptx2 for FSH) has been shown to be sufficient to induce activity of the transiently transfected LHß and FSHß promoters in reporter gene assays in heterologous cells (9, 20, 27, 41, 55, 56, 61, 67). However, LHß and FSHß gene expression in the developing gonadotrope appears only following the migration of the gonadotropin releasing hormone (GnRH) neurons in the hypothalamus and GnRH delivery to the pituitary, which starts around E16. This indicates a role for GnRH in initiating gonadotropin gene expression, which might be distinct from its stimulating increases in gonadotropin gene expression in mature gonadotropes, in which the gonadotropin genes are already expressed at a basal level. Gonadotropin expression continues to increase in response to GnRH during gestation (18, 43). After birth, however, the levels of LH and FSH vary in different species: in mice, levels of LH and FSH increase to day 12, corresponding with increases in GnRH levels and its pulsatile secretion as the hypothalamus matures during the first 2 weeks postparturition (43). In primates, gonadotropin synthesis is repressed soon after birth as a result of insufficient release of GnRH from the hypothalamus, and it is reversed at puberty when GnRH synthesis and release are restored (18, 47). Subsequently, many mammals and nonmammalian species have reproductive seasons or extended cycles, which are reinitiated in response to central nervous system-induced GnRH synthesis and release. Thus, a clear role is evident for GnRH in not only stimulating gonadotropin gene expression above basal levels but also overcoming a repressed state of inactivity of these genes. Although the mechanisms through which GnRH actively stimulates LHß and FSHß gene transcription have been described in some detail, there is currently no information on how GnRH overcomes repression in order to terminate reproductively inactive stages.
Reversible suppression of gene expression is often achieved through the actions of DNA-associated factors, such as nuclear receptors, some of which recruit corepressors and chromatin-modifying enzymes. These repressors act collectively to block the binding sites of activators, to prevent interaction with the general transcription machinery, and/or to compact the chromatin, making it less accessible to DNA-binding activators. The best-studied chromatin modification leading to chromatin compaction is histone deacetylation, in which histone deacetylases (HDACs) remove acetyl groups from the lysine residues of core histone N-terminal tails through a reaction that is easily reversed by histone acetyltransferases. The absence of acetyl groups on these lysines restores the positive charge to the histones and thus strengthens their interaction with the DNA, increasing chromatin compaction and making the chromatin less accessible to the activators. The modification of these lysines may also provide specific binding surfaces for the recruitment of additional proteins (30, 54).
Mammalian HDACs are grouped into three classes based on their sequence similarity to Saccharomyces cerevisiae histone deacetylases. Class I includes HDACs 1, 2, 3, 8, and 11 and class II includes HDACs 4, 5, 6, 7, 9, and 10, while the third class of HDACs is the conserved NAD-dependent Sir2 family of deacetylases. Although the class I HDACs are mostly nuclear, class II HDACs can be found in the nucleus and/or cytoplasm, with the subclass IIa HDACs actively shuttling between the two cellular localizations. Notably, HDAC6 has a rather different function as it is primarily found in the cytoplasm, where it deacetylates
-tubulin, thereby regulating microtubule-dependent cell motility (8, 29, 57, 64).
In comparison to the class I HDACs, class II HDACs are much larger proteins and contain several domains for interacting with diverse proteins, such as other HDACs, transcription factors, and corepressors. HDACs are usually found associated with the chromatin in multiprotein complexes together with corepressors that lack their own enzymatic activity but help recruit the HDACs and/or stabilize the complex (13, 24). Two such corepressors, the nuclear receptor corepressor (NCoR) and silencing mediator of retinoic and thyroid hormone receptors (SMRT), were first described as corepressors for the unliganded thyroid hormone and retinoic acid receptors but also serve as common corepressors for other DNA-bound factors (13). NCoR contains three distinct repression domains in its N terminus which allow interaction with several HDACs and also with another common corepressor, mSin3A. Sin3 is a large multidomain protein that can form a scaffold upon which the rest of the complex assembles. It also interacts directly with HDACs 1 and 2, several class IIa HDACs, and various DNA-bound factors (13, 17).
Regulation of the activity of repressive complexes may be directed at any or several of its components. In the case of nuclear receptors, the binding of a ligand induces conformational change of the receptor so that its interaction with the HDAC-containing repressive complex is lost, and histone acetyltransferases are recruited instead (13, 26, 48). The activity of HDACs can also be regulated: for example, phosphorylation of several class IIa HDACs by calcium/calmodulin-dependent protein kinases (CaMKs) or possibly protein kinase D allows their interaction with 14-3-3 proteins, leading to their subsequent nuclear export (16, 22, 32, 37, 39, 44, 58). In contrast, extracellular signal-regulated kinase 1 and 2 was reported to phosphorylate HDAC4, leading to its nuclear accumulation, while the activity of HDAC3 is increased following its interaction with protein phosphatase 4 (68, 69).
In an attempt to explore the ways in which gonadotropin gene expression is repressed, we revealed initially that the expression of both LHß and FSHß genes is repressed in the
T3-1 murine gonadotrope cells by HDAC activity and that GnRH is able to overcome this repression. These cells were produced by targeted oncogenesis and are thought to represent a partially differentiated gonadotrope around E11.5; they do not express the gonadotropin ß-subunit genes, although the transcription factors known to activate them are present (1, 14, 46). We hypothesized that to derepress these genes by disrupting the HDAC-containing repressive complexes, GnRH must employ a distinct mechanism that likely differs from the activation of LHß and FSHß gene transcription above basal activity. The aim of this study was thus to characterize these repressive complexes and to determine the mechanisms through which GnRH is able to overcome their effects.
|
|
|---|
T3-1 cells were cultured in minimum essential medium, supplemented with 10% fetal calf serum, 10 mM HEPES, 0.1 mM minimum essential medium nonessential amino acids, 1 mM sodium pyruvate solution, 100 U/ml penicillin, and 100 µg/ml streptomycin (Gibco-Invitrogen). During the course of the study, at least three different batches of cells from different sources were used in order to confirm the consistency of the results. The more mature gonadotrope LßT2 cells, which express both subunit genes (LHß quite abundantly and FSHß at a much lower level) and represent gonadotropes at approximately E16.5, were cultured in Dulbecco's modified Eagle's medium containing 4.5 g/liter glucose with 10% certified fetal calf serum, 10 mM HEPES, 100 U/ml penicillin, and 100 µg/ml streptomycin (Gibco-Invitrogen). Cells were cultured in six-well plates unless otherwise stated. All cells were maintained at 37°C in 5% CO2. Transfections in both cell types were carried out at 50 to 60% confluence as described previously (40) using FuGene6 (Roche Diagnostics, Basel, Switzerland) or according to the method of Luo et al. (35) using GenePORTER 2 (Gene Therapy Systems, San Diego, CA) transfection reagents. As appropriate, cells were treated with GnRH (D-Ala6-LH-releasing hormone [LHRH], where indicated; otherwise, 10 to 100 nM buserelin for 1 to 24 h) and/or trichostatin A (TSA; 20 to 200 ng/ml for 24 h, added at the time of GnRH), cyclosporine A (20 µM, added 1 h before the GnRH), or KN-93 (10 µM, added 30 min before the GnRH) (all from Sigma-Aldrich, St. Louis, MO); all were added at 0.1% of the culture volume. Reporter gene assays were carried out using 600 bp of the proximal murine FSHß gene promoter fused to the firefly luciferase gene as described previously (41). Firefly luciferase values were normalized to those of Renilla luciferase which was cotransfected as an internal control. Experiments were carried out on at least three separate occasions, and representative results are shown.
Plasmid constructs. For construction of small interfering RNA (siRNA)-encoding plasmids, the 19-nucleotide gene-specific sequences targeting each gene, which were repeated in reverse orientation with a 9-nucleotide spacer and with BglII- and HindII-compatible overhangs (according to instructions of Oligoengine, Seattle, WA) were as follows (corresponding NCBI accession numbers are given in parentheses): HDAC1 (NM_008228), CCAGAACACTAACGAGTAC; HDAC 2 (NM_008229), GAAGACCCGGACAAAAGAA; HDAC3 (NM[010411]), TGCTGAACCATGCACCCAG; HDAC4 (taken from XM_358028, in which the boldface C corresponds to a T in later entries e.g., NM_207225), ATGCGAGTGCATCCGCGGA; HDAC5 (NM_010412), GCAAGCATTCTACAACGAT; HDAC6 (AF006603), CCAGGACGATCTCCAAGAT; HDAC7 (AF207749), TTCAACTTTAGGCCCTCGG; HDAC8 (BC061257), GGAGGCTATAACCTTGCCA; HDAC9 (NM024124), CCACACATCACTGGATCAA; HDAC10 (NM_199198), CTTCTCCACTCCACTGCCA; HDAC11 (BC016208), TCATTGATCTCGATGCCCA; mSin3A (NM_011378), GTACTGGTGCAACTGGTGG; NCoR, AGGAAGAGTGTTCCTGATT; SMRT, TGACTACATCACCTCGCAG (NCoR and SMRT targets were taken from Zakaria et al. [67]). The siRNA construct targeting SMRT was also cotransfected with an equal amount of an additional construct containing the sequence CCCATAGAATCAAAGCACC. All siRNA oligonucleotides were checked by a BLAST search against the mouse genome to minimize any possibility that they might cross-react with other transcripts and to confirm that there is no sequence similarity in the sequences chosen to make these constructs with any of the other HDACs.
After constructs were annealed to their complementary sequences, the double-stranded DNA fragments were inserted into the BglII/HindIII-digested pSUPER vector (Oligoengine, Seattle, WA). All constructs were verified by sequencing, and their successful knockdown of target proteins was verified by Western analysis. In controls, the empty pSUPER vector was transfected, while a similar construct targeting green fluorescent protein (GFP) (35) was transfected to confirm that there was no nonspecific effect on the individual HDAC expression levels. All constructs were transfected at 2 to 4 µg of DNA per six-well plate.
Expression vectors for mouse Nur77, MEF2A, and MEF2D were created by inserting the coding sequences, amplified from LßT2 cell cDNA, into the pCS2 plasmid vector. The dominant negative Nur77 (dnNur77) was created by amplifying Nur77 without its activation domain (a deletion of the N terminus upstream of residue 152) as previously described (4). The expression vector for constitutively active calcineurin was created by amplification of its catalytic subunit A without the calmodulin-binding and autoinhibitory domains. The S354A and S354E mutant Nur77 constructs were a gift from Lester Lau (University of Illinois at Chicago). The pEGFP-HDAC4 (where EGFP is enhanced GFP), pEGFP-HDAC5, and pEGFP-HDAC6 constructs and the pEGFP-HDAC4(S246A S467A S632A) construct were a gift from Xiang-Jiao Yang (McGill University, Canada). The pEGFP-HDAC5(S259A S498A) construct was a gift from Eric Olson (University of Texas Southwestern Medical Center). The pYFP-HDAC7 (where YFP is yellow fluorescent protein) construct was a gift from Hung-Ying Kao (Case Western Reserve University). The dominant negative CaMKI (dnCaMKI) construct was a gift from Tom Soderling (Oregon Health Science University). The expression vectors were transfected at 1 to 1.5 µg per six-well plate.
RNA extraction, reverse transcriptase PCR, and real-time PCR. RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA), and the total RNA (5 µg) was reverse transcribed using either Superscript II (Invitrogen) or Moloney murine leukemia virus (Promega, Madison, WI) reverse transcriptase and oligo(dT) primers (5 mM; New England Biolabs, Beverly, MA). PCR amplification of LHß or FSHß transcripts was carried out using various sets of primers, some of which spanned introns, as indicated in the figure legends. Nur77 and calcineurin catalytic subunits were amplified using primers targeting 380 bp of the Nur77 coding sequence or the full-length 1.5-kb calcineurin catalytic subunit, respectively. Control reactions were carried out in which the reverse transcriptase was omitted to ensure that the amplicon did not result from genomic DNA contamination. Internal controls comprised amplification of the mouse 60s ribosomal protein (60sRP) or ß-actin. Quantitative real-time PCR was carried out essentially as described previously (35) using primers to produce 120-bp amplicons from the ß-subunit cDNAs and a 100-bp amplicon for 60sRP as an internal control. The comparative cycle threshold method was used to compare mRNA levels in the various samples to those in untreated samples after their normalization to the internal control. All samples were assayed in duplicate.
ChIP assays. Chromatin immunoprecipitation (ChIP) assays were carried out as previously described (35). Briefly, proteins and DNA were cross-linked using 1.5% formaldehyde for 15 min at 37°C and arrested using 1 M glycine. The cells were washed twice with phosphate-buffered saline (PBS) before being collected in 1 ml of PBS with protease inhibitors. The cells were then pelleted before resuspension in lysis buffer and were incubated on ice for 15 min before sonication to yield genomic DNA fragments between 500 bp and 1 kb. Cell debris was then precipitated (13,000 rpm for 10 min at 4°C), and the supernatant was transferred to fresh tubes. A 20-µl aliquot was removed as input, and the remainder was diluted and precleared with protein A-Sepharose beads before overnight incubation with primary antisera targeting the following: HDACs 1, 3, 4, 5, 6, and 7 (Cell Signaling Technology); HDACs 2 and 11 (Abcam); HDAC9 (Southwestern Medical Center, Center for Biomedical Inventions); HDAC10 (Novus Biologicals); mSin3A (Upstate Biotechnology); and HDAC8, SMRT, Nur77, pNur77, and MEF2 (Santa Cruz Biotechnology). For the controls, antiserum was omitted or replaced with normal rabbit serum. The antibody-bound complexes were captured with protein A-Sepharose beads and washed in a series of increasing salt concentrations. The complexes were then eluted, and the cross-links were reversed. Proteinase K treatment was carried out before phenol-chloroform extraction of the DNA. Regions of the proximal promoters of the LHß or FSHß genes were amplified from input and ChIP samples, using the following primers: 5'-GTGAAGCCCACCCACCACGC-3' and 5'-CCTTGGGCACCTGGCTTTAT-3' to amplify the LHß proximal promoter from 579 to 13 bp upstream of the transcriptional start site; 5'-CACAGCCCATAGGAACAAGA-3' and 5'-CCAAAGCAGTCTAAATGCCA-3' to amplify the FSHß proximal promoter from 436 to 137 bp from the transcriptional start site. All ChIP experiments were carried out on at least three separate occasions, and representative results are shown.
Western blot analysis. Western blot analysis was carried out as previously described (35) using the same antisera as for ChIP analyses or antisera targeting the following: HDAC9 (Abcam), pCaMKI, pCaMKII, pCaMKIV or glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Santa Cruz Biotechnology); or pHDAC4 (S632) and pHDAC5 (S498) (Signal Antibody Technology, San Francisco, CA).
Fluorescence microscopy.
The
T3-1 cells (1 x 105) were plated on 22-mm ethanol-washed grade 1 coverslips in six-well plates and transfected 24 h later with 500 ng of DNA. After 24 to 48 h, GnRH (10 nM) was added 2 to 8 h prior to fixing of both treated and untreated cells. The medium was aspirated, and cells were washed once with Hanks balanced salt solution before being fixed for 15 min at room temperature with 4% paraformaldehyde (Sigma). Thereafter, cells were washed twice with PBS and subsequently stained at 37°C with DAPI (4',6'-diamidino-2-phenylindole) for 15 min. The cells were washed once more with PBS and rinsed with distilled water before the coverslips were mounted on glass slides using an antifading solution (PBS containing 15% polyvinyl alcohol, 33% glycerol, and 0.1% sodium azide). The preparations were viewed under an Olympus IX81 confocal microscope (FV500 confocal system). The localization of the HDACs was noted in an average of 60 cells for each construct transfected at every time point, and representative pictures are shown.
|
|
|---|
T3-1 cells, which do not normally express either the LHß or the FSHß gene, were exposed to the nonspecific inhibitor of class I and class II HDACs, TSA (at 0, 20 or 200 ng/ml), and/or to GnRH (100 nM D-Ala6-LHRH) for 24 h. Reverse transcription-PCR (RT-PCR) over 25 cycles failed to detect either transcript in untreated cells, while either TSA or GnRH was sufficient to facilitate expression of both genes, with TSA having an apparent dose-related effect. The combined treatment did not increase levels beyond those of the GnRH treatment alone (Fig. 1A).
![]() View larger version (41K): [in a new window] |
FIG. 1. LHß and FSHß gene expression is repressed in immature gonadotropes by HDACs, and this is overcome by GnRH. RT-PCR analysis of LHß and FSHß mRNA levels was carried out in immature T3-1 (A) and mature LßT2 (B) gonadotrope cells following a 24-h exposure to TSA (20, 100, or 200 ng/ml) and/or GnRH (D-Ala6-LHRH; 100 nM) in three repeats for each treatment. Total RNA was isolated from the cells, and cDNA was synthesized and used as template for PCR. Control reactions were carried out in which the reverse transcriptase was omitted to ensure that the amplicon did not result from genomic DNA contaminations (not shown). The primers were designed to amplify fragments of the LHß and FSHß cDNAs, while amplification of a fragment of the mouse 60sRP cDNA is shown as a control. Total RNA was extracted from T3-1 or LßT2 cells treated with TSA (C) or GnRH (D), and quantitative real-time PCR was performed. Changes in cycle threshold values were normalized to those of 60sRP and compared to the levels in untreated controls. Values are means ± standard errors of the means (n = 3). *, P < 0.05; **, P < 0.005; ***, P < 0.0001.
|
These findings were confirmed using quantitative real-time PCR, which showed an increase in both transcript levels in
T3-1 cells following 8 or 24 h of treatment with TSA (100 ng/ml), but only the FSHß transcript responded to TSA in the LßT2 cells (Fig. 1C). Both transcripts were elevated in both cell lines following 8 or 24 h of GnRH treatment (Fig. 1D). This indicates that both genes are repressed by HDACs in the
T3-1 cells but only the FSHß gene is repressed by HDACs in the LßT2 cells and that GnRH is able to overcome this repression.
Distinct sets of HDACs repress the LHß and FSHß genes. In order to understand more about the mechanism of repression of these genes in the immature cells, we carried out ChIP analysis to identify the HDACs that are associated with each of the ß-subunit gene promoters. HDACs 1, 4, 5, 7, 8, 10, and 11 were found associated with the LHß gene promoter, whereas HDACs 2, 3, 4, 9, and 10 were found associated with the FSHß promoter (Fig. 2A). These experiments were repeated using antisera against the class I and some of the class II HDACs that associate with these genes, following GnRH treatment for 6 h, to see whether they were released. This time frame was chosen because the derepression of the LHß and FSHß gene expression was usually apparent following an 8-h exposure to GnRH. This revealed dissociation of HDACs 3, 4, and 5 from the LHß and/or FSHß promoters following the GnRH treatment, while HDACs 1 or 2 were still associated (Fig. 2B).
![]() View larger version (55K): [in a new window] |
FIG. 2. Distinct sets of HDACs are associated with LHß and FSHß genes in the immature gonadotropes. (A) ChIP analysis was carried out in duplicate to determine which HDACs are associated with the LHß and FSHß gene promoters in immature T3-1 cells; an aliquot from the same cells before precipitation was designated as the input sample. PCR amplified a 567-bp or 300-bp region of the LHß or FSHß proximal promoters, respectively. (B) The ChIP analysis was repeated as relevant for HDACs 1 to 5 on LHß (upper panels) or FSHß (lower panels) gene promoters, following a 6-h GnRH exposure; the treatments were carried out in duplicate. Ab, antibody.
|
![]() View larger version (50K): [in a new window] |
FIG. 3. Knockdown of the associated HDACs reveals their crucial roles in the repression. (A) Transfection with an siRNA construct (2 to 4 µg) targeting the HDACs found associated with the respective genes was employed to knock down the HDAC expression levels in T3-1 cells, and the efficiency was verified by Western analysis. The left lane () shows the protein in nontransfected cells, the middle lane (+) is following transfection with the specific siRNA, and in the right lane (c) the sample is from cells transfected with a control siRNA sequence. Also shown in the lower box in each row is the loading control, GAPDH or polymerase II. (B) Total RNA was isolated 48 h after transfection with the various siRNA HDAC constructs, and RT-PCR analysis of LHß and FSHß mRNA levels was carried out. The primers designed to amplify the LHß transcript targeted two different exons, while primers targeting FSHß and 60sRP were as described in the legend of in Fig. 1. Also shown are untreated (first lane) or GnRH-treated (100 nM for 24 h; next three lanes) controls. (C) ChIP was carried out to test the association of HDACs 1 and 5 (for LHß) or 2 and 3 (for FSHß) following siRNA-mediated knockdown of HDAC4. All transfections were carried out in duplicate 48 h before harvest. siHDAC4, HDAC4-targeting siRNA construct; , antisera against.
|
Corepressors that repress the FSHß gene are identified.
In order to characterize further the repressive complexes at each of these gene promoters, we evaluated the effect of siRNA-mediated knockdown of mSin3A, SMRT, or NCoR; the degree of knockdown was assessed by Western analysis (Fig. 4A). Transfection of the siRNA vector to reduce mSin3A expression was sufficient to restore expression of the FSHß gene in both cell lines, while the LHß transcript remained undetected in the
T3-1 cells, and its levels were unaffected in LßT2 cells. Similarly, transfection of the siRNA constructs targeting SMRT had a clear stimulatory effect on the FSHß transcript levels in both
T3-1 and LßT2 cells while apparently not affecting the levels of the LHß transcript. The siRNA construct targeting NCoR appeared to have no effect on the levels of either transcript in both cell lines (Fig. 4B).
![]() View larger version (48K): [in a new window] |
FIG. 4. Corepressors that repress the FSHß gene in both cell types are identified. siRNA constructs (2 to 4 µg) targeting the corepressors mSin3A, SMRT, or NCoR were transfected into T3-1 and LßT2 cells. (A) Western analysis was utilized to confirm the degree of knockdown as described in the legend of Fig. 3A, except that the control siRNA for NCoR was against SMRT. (B) RT-PCR was carried out to assess the effects of these knockdowns on LHß and FSHß mRNA levels in both cell lines as described in the legend of Fig. 1, with ß-actin as an internal control. All transfections were carried out in duplicate. (C) ChIP analysis was carried out in both cell lines, using antisera to mSin3A in untreated or GnRH-treated cells (100 nM for 6 h), as indicated. DNA fragments were amplified as described in the legend of Fig. 2B from the precipitate and input samples. ChIP analysis was also carried out in T3-1 cells after transfection of the siRNA construct to knock down mSin3A (D) or SMRT (E) expression and test the association of HDACs 2, 3, and 4 with the FSHß gene, as described in the legend of Fig. 2. Ab, antibody; siSin3A, Sin3A-targeting siRNA construct; siSMRT, SMRT-targeting siRNA construct.
|
In order to understand the role of these cofactors in the FSHß-repressive complexes, ChIP was carried out to test the association of HDACs 2, 3, or 4 after siRNA-mediated knockdown of mSin3A or SMRT. The mSin3A knockdown abolished association of HDACs 2 and 4 and reduced that of HDAC3 to levels that were barely detectable (Fig. 4D), while the knock-down of SMRT led to a loss of association of all three HDACs (Fig. 4E). Coimmunoprecipitation experiments indicated that mSin3A and SMRT do not coprecipitate in these cells (not shown). However, both mSin3A and SMRT coprecipitate with HDAC3, while mSin3A also coprecipitates with HDACs 1, 2, or 4 (not shown).
GnRH causes the nuclear export of HDACs 4, 5, and 7. Knowing that GnRH activates a number of phosphorylation pathways, some of which might target class IIa HDACs and alter their cellular localization, we examined the localization of four class II HDACs following GnRH treatment in the immature gonadotrope cells. EGFP-tagged HDAC 4, 5, or 6 or YFP-tagged HDAC7 was transfected into the cells, and after 24 to 48 h the cells were treated with GnRH (10 nM) for 0 to 8 h. HDAC4 was found initially distributed throughout the cell (in 86% of the cells in which it was expressed), but after 4 to 8 h of treatment, it was exclusively cytoplasmic in the majority of expressing cells (59 to 63%) (Fig. 5A). HDAC5 was predominantly exclusively nuclear in untreated cells (80%) but already after a 2-h treatment was exclusively cytoplasmic in most cells (82%) (Fig. 5B). HDAC7 was initially pan-cellular in most cells (92%) but was found exclusively in the cytoplasm in the majority of cells (67 to 73%) after 4 to 8 h of treatment (Fig. 5C). HDAC6, which served as a control, was expressed only in the cytoplasm, where it remained following the treatment (Fig. 5D).
![]() View larger version (78K): [in a new window] |
FIG. 5. GnRH stimulates nuclear export of HDACs 4, 5, and 7. Expression vectors (500 ng) encoding fluorescently tagged class IIa HDACs 4, 5, and 7 (A to C) or HDAC6 (D) were transfected into T3-1 cells which, at 24 to 48 h after transfection, were then exposed to GnRH (10 nM for 0 to 8 h). (E and F) Alternatively, vectors encoding mutant HDAC4 or -5 in which the serines (in HDAC4, residues S246, S467, and S632; in HDAC5, residues S259 and S498) were mutated to alanines, were transfected, and cells were similarly treated. Cells were then stained with DAPI; micrographs are representative of the localization of the HDACs in an average of 60 cells that were noted at each time point. Also shown is the negative control in which none of the HDAC constructs was transfected. Yellow scale bars (in negative controls), 10 µm; white scale bars, 5 µm.
|
GnRH-mediated derepression of the FSHß but not the LHß gene involves activation of CaMKI and its phosphorylation of HDACs 4 and 5. Our results indicate that the complexes repressing expression of these genes in the immature gonadotropes include several class IIa HDACs which move out of the nucleus following GnRH treatment, possibly as a result of their phosphorylation. Previous studies have indicated that CaMKI and CaMKIV can phosphorylate these HDACs, though neither has previously been linked to GnRH signaling; we therefore sought to determine which of these enzymes is activated by GnRH by examining changes in the levels of phosphorylated CaMKs (pCaMKs). After GnRH treatment, levels of both pCaMKI and pCaMKII were increased but with different kinetics: pCaMKI showed a gradual increase through the first hour of treatment, at which point it was at a considerably higher level than in the untreated controls. pCaMKII, on the other hand, showed a rapid response within the first minute, but the levels then remained similarly elevated for the duration examined. The pCaMKIV was barely detectable, and its levels were apparently unaltered by the GnRH treatment (Fig. 6A).
![]() View larger version (45K): [in a new window] |
FIG. 6. GnRH derepression of the FSHß gene involves CaMKI. (A) Western analysis was carried out to detect phosphorylated forms of CaMKI, -II, and -IV in T3-1 cells after exposure for 0 to 60 min to GnRH using antisera as marked; GAPDH is shown as a loading control, to which CaMK levels were normalized, and these values are expressed as a ratio to the levels in untreated cells. (B) T3-1 cells were exposed to GnRH (10 nM for 8 h) and/or the CaMK inhibitor KN-93 (10 µM; added 30 min before the GnRH) before RT-PCR analysis of FSHß and LHß mRNA levels. (C) Similarly, the dnCaMKI expression vector (1.5 µg) was transfected into cells 16 h before treatment with GnRH (10 nM for 24 h), and the effect on GnRH derepression of both genes was assessed by RT-PCR in the same way. Transfections and treatments were carried out in duplicate. (D) Levels of phosphorylated HDAC4 and -5 (pHDAC4 and -5) were assessed by Western analysis in control cells and cells treated with GnRH (2 h), with or without transfection (24 h before) of the dnCaMKI construct. (E) Wild-type (wt) or mutant (mu) HDAC4 and -5 constructs (as described in the legend of Fig. 5) were overexpressed in the presence or absence of GnRH, and their effects on the derepression of LHß and FSHß were assessed by RT-PCR, as described in the legend of Fig. 3. Transfections and treatments were carried out in duplicate.
|
In order to confirm the connection between GnRH activation of CaMKI and the phosphorylation of the class II HDACs, we carried out Western analysis to measure the changes in levels of phosphorylated HDAC4 and HDAC5 after GnRH treatment, with or without transfection of the dnCaMKI construct. The levels of both phosphorylated HDACs were clearly increased following GnRH treatment, and this was abated with transfection of the dnCaMKI construct (Fig. 6D).
We reasoned that overexpression of the class II HDACs would likely allow their replacement of the endogenous HDACs on the gonadotropin gene promoters and that they would be subject to similar posttranslational regulation. We therefore transfected wild-type or mutant HDAC4 or HDAC5 to assess the importance of the CaMK phosphorylation sites in the derepression by GnRH. Notably, GnRH was able to derepress the LHß or FSHß gene following transfection of the wild-type HDAC4, but its effect was abolished following transfection of the mutant HDAC4. Similarly, the mutant, but not the wild-type, HDAC5 prevented the GnRH effect on the LHß gene, while interestingly overexpression of either form of HDAC5 had a repressive effect on GnRH-induced derepression of the FSHß gene (Fig. 6E).
GnRH regulation of Nur77 plays a role in derepression of the FSHß gene in the immature gonadotropes.
In order to try to elucidate the DNA-bound transcription factor(s) responsible for recruiting the repressive complexes to the LHß and FSHß gene promoters, we investigated the effects of various transcription factors on activating expression of these genes. We found that overexpression of Nur77 or MEF2D markedly increased the transcript levels of the FSHß gene without affecting those of LHß, while a marginal effect on the FSHß gene was also seen following overexpression of MEF2A (Fig. 7A). We tested the effects of overexpression of these transcription factors on the promoter activity of FSHß in transient transfection assays and found that Nur77 stimulated its activity, while MEF2A or -D had no effect (Fig. 7B). We confirmed a role for Nur77 in mediating the GnRH derepressive effect on FSHß gene expression by transfecting dnNur77, which expresses the transcription factor without its activation domain, and abolished the effects of GnRH (Fig. 7C). However, ChIP assays showed that Nur77 and MEF2 (the antisera recognizes both MEF2A and MEF2D) were associated with the FSHß gene promoter in
T3-1 cells both before and after GnRH treatment (Fig. 7D and E).
![]() View larger version (34K): [in a new window] |
FIG. 7. Nur77 induces expression of the FSHß gene in the immature gonadotropes and plays a role in the GnRH derepressive effect. (A) Nur77, MEF2A, or MEF2D expression vectors (1 µg) were transfected into T3-1 cells, and the effects on FSHß and LHß mRNA levels were assessed 40 h later by RT-PCR, as described in the legend of Fig. 1. (B) The effects of the same expression vectors (100 ng) on the transiently transfected FSHß gene promoter fused to a firefly luciferase reporter gene (200 ng) were also tested. Firefly luciferase values were normalized to those of Renilla luciferase, and these values are expressed as a ratio to levels in untreated cells. The empty promoterless vector (pGL3) was also transfected as a control. Values are means ± standard errors of the means (n = 4 to 6). (C) The role of Nur77 in the GnRH effect on the FSHß gene was tested using a dnNur77 which was overexpressed, and cells were then treated with GnRH before RT-PCR to detect FSHß mRNA; ß-actin was used as a control. Transfections and treatments were carried out in duplicate. ChIP analysis was carried out using antisera to Nur77 (D) or MEF2 (recognizes MEF2A, -C, and -D) (E) to test association of these proteins with the FSHß gene promoter in untreated and GnRH-treated (10 nM for 2 h) T3-1 cells, as described in the legend of Fig. 2A. Ab, antibody.
|
![]() View larger version (36K): [in a new window] |
FIG. 8. Calcineurin mediates the GnRH effect on Nur77. (A) Western analysis was carried out on T3-1 cells following treatment for 0 120 min with GnRH using antiserum that recognizes the S354 phosphorylated Nur77 (pNur77), the total Nur77, or GAPDH as a control. (B) The pNur77 antisera was also used for ChIP analysis to test its association with the FSHß gene promoter in untreated and GnRH-treated cells (10 nM for 2 h), carried out in triplicate. (C) The implication of phosphorylation in the regulation of FSHß transcription was tested by overexpressing Nur77 with residue S354 mutated to an alanine or a glutamic acid before RT-PCR to assess changes in the FSHß mRNA levels. (D) The levels of the calcineurin catalytic subunit mRNA in untreated or GnRH-treated T3-1 cells were assessed by RT-PCR. (E and F) T3-1 cells were treated with cyclosporine A 1 h before addition of GnRH (100 nM) for 1 h (E) or 8 h (F), and the effects on mRNA levels of Nur77 (E) or FSHß (F) were assessed by RT-PCR, as described before. (G) The effects of calcineurin overexpression on pNur77 levels were tested in T3-1 cells and assessed by Western analysis as described for panel A, using polymerase II (Pol II) as a loading control. cycloA, cyclosporine A; Ab, antibody.
|
|
|
|---|
Partial characterization of the repressive factors associated with each of these genes has revealed that they include distinct sets of HDACs and corepressors. The LHß gene promoter appears associated with a particularly large number of HDACs which, based on the effects of the siRNA-mediated knockdown, do not have redundant functions. Although the requirement for so many different proteins with apparently similar enzymatic activities remains puzzling, it is supported by evidence of severe phenotypes resulting from mutations in genes encoding individual HDACs (64). The corepressor SMRT does not appear to repress this gene, and its knockdown did not allow LHß gene expression, contrasting strongly with the effect of knockdown of almost any of the HDACs on expression of this gene; it was also not found associated with the gene in untreated cells.
The FSHß gene promoter is associated with two class I and three class II HDACs, together with mSin3A and SMRT which likely act as scaffolds. mSin3A has previously been shown to interact with HDAC1/2 and SMRT, as well as a number of other mSin3A-associated proteins (17, 24, 52), and our studies confirmed that mSin3A and HDAC2 do coprecipitate in these cells. SMRT reportedly associates either with mSin3A-HDAC1/2 complexes or with HDAC3 in Sin3-independent complexes which lack HDAC1/2 (21, 24, 28). We found that HDAC3 coprecipitated with both mSin3A and SMRT, but mSin3A and SMRT did not coprecipitate, while HDAC4 appears crucial in the recruitment of HDAC3 but not HDAC2. This suggests that there may be two distinct corepressor complexes on the FSHß gene promoter, one with mSin3A-HDAC2 and the other with SMRT-HDAC3, while HDAC4 is likely found in both complexes and may form a key link in the recruitment of the HDAC3-containing complex, as has been shown previously (8). However, the knockdown of either mSin3A or SMRT resulted in the virtual loss of the associated HDACs and was sufficient to restore FSHß gene expression, indicating a clear functional interaction. This might well involve the recruitment of additional histone-modifying enzymes to this locus: mSin3A has been reported to associate with the Swi/Snf chromatin-remodeling complex and also to recruit DNA and histone methylases to the DNA (52).
In contrast to mSin3A, which clearly dissociated from the FSHß gene promoter following GnRH treatment, SMRT remained associated and was similarly found at the LHß gene promoter following GnRH treatment. This is not totally surprising because SMRT and/or the related NCoR are often found associated with actively transcribed genes, and ChIP carried out at frequent intervals has suggested mechanisms of their cycling on and off certain promoters during the transcriptional process (12, 25, 45). As our ChIP assay was carried out only at one time point, we do not know whether the association seen after GnRH exposure is transitory. The association of HDACs 1 or 2 from the respective promoters appeared similarly unaffected by the GnRH treatment. There is, however, mounting evidence that class I HDACs may play a role in ongoing transcriptional activation of certain genes, and in yeast the deacetylation of specific lysines was found to be positively correlated with transcription (12, 25, 31, 42, 59). Notably, knockdown of either HDAC1 or -2 failed to facilitate the respective gene expression, lending weight to the possibility of the essential role of these HDACs in gene activation. Given that HDAC2 is likely recruited to the repressed FSHß gene specifically through mSin3A, we envisage that after GnRH treatment, HDAC2 can be recruited to the gene through a different mechanism, possibly involving an altered SMRT complex which no longer contains HDAC3. SMRT might also recruit HDAC1 to the activated LHß gene promoter through a similar mechanism that requires further investigation.
Our results showing that GnRH causes dissociation of the HDACs 3, 4, and 5 from the respective genes and that the knock-down of the relevant class IIa HDACs is sufficient to derepress the gene expression indicate a crucial role for the class II HDACs, even though their independent deacetylase enzymatic activity has not been proven in vitro (11). These class IIa HDACs more likely have a crucial role in formation and/or stabilization of the complex, which is supported by previous suggestions that they do not function in an enzymatic capacity but rather recruit additional enzymes via the corepressors (8, 11, 57). Furthermore, these class IIa HDACs are much more regulated than the class I HDACs; this occurs at the level of their expression, cellular localization, and protein-protein interactions, and they can be regulated, for example, by kinases, calcium influx, ubiquitylation, or sumoylation (8, 57, 64). This ability to respond to common intracellular signals, while also playing a key role in the stability of the complex, would make them ideal candidates for mediating regulation of the function of the catalytic class I HDAC-containing repressive complex.
We found that HDACs 4, 5, and 7 translocate into the cytoplasm following GnRH exposure by means of a mechanism that, at least for HDACs 4 and 5, requires the serines which are targeted by CaMKs and recognized by 14-3-3 proteins (38, 58). The actions of the various CaMKs have previously been shown to overlap, and specificity is thought to relate to their patterns of expression, spatial localization, and activation (5, 51). Notably, only CaMKI and -II appear to be activated by GnRH treatment; this effect on CaMKII has been reported previously (19). The fact that the GnRH effect on the FSHß gene was blocked by KN-93 treatment and by the dnCaMKI indicates that GnRH-induced CaMKI is likely responsible for the GnRH-induced translocation of the HDACs, causing disruption of the repressive complex. This was confirmed by the finding that the dnCaMKI reduces the GnRH-stimulated increase in levels of phosphorylated HDACs 4 and 5. The overexpression of the mutant HDAC4 confirmed that the phosphorylation is required for derepressing both genes, while the mutant HDAC5 similarly prevented derepression of the LHß gene. Inhibition of the GnRH derepressive effect on the FSHß gene following overexpression of the wild-type or the mutant HDAC5 was surprising but might be due to effects on Nur77 gene expression, which HDAC5 also regulates, involving stimulation of MEF sumoylation which inhibits transcription (15).
Neither CaMK inhibitor blocked the GnRH effect on the LHß gene, indicating that CaMKI-induced phosphorylation of HDACs is not required for derepression of the LHß gene. Instead, GnRH likely directs its derepression effect on the LHß gene downstream of CaMK activation. We can thus hypothesize that GnRH acts at a different level to remove the repressive complex from the LHß gene, presumably through the DNA-bound transcription factor(s) or at an associated corepressor, in a CaMK-independent manner. Identification of this as yet elusive repressor will enable us to examine how it is recruited to the LHß gene and how its activity is regulated and will allow for a greater understanding of the repression of the LHß gene.
The ability of GnRH to derepress the FSHß gene is also dependent on its ability to activate Nur77. Nur77 has previously been reported to be dramatically up-regulated by GnRH in gonadotropes (28, 63), and its expression in T cells is regulated by MEF2D, whose overexpression we also found stimulated FSHß gene expression. MEF2D can act as a repressor or activator of Nur77, depending on whether it interacts with class IIa HDACs or with coactivators (34, 66). As a repressor, MEF2 complexes with the corepressor Cabin1 which recruits mSin3A, HDAC1/2, and HDAC4 (66). In the event of calcium signaling, MEF2 activity is reversed as a result of activated calmodulin, which displaces Cabin1 and competes with MEF2D for HDAC4 binding, leaving MEF2D free to interact with the coactivator p300. In addition, calmodulin-activated calcineurin causes the translocation of nuclear factor of activated T cells (NFAT) which complexes with MEF2D on the Nur77 promoter, thereby facilitating recruitment of p300 (2, 65, 66). We found MEF2 associated also with the FSHß gene in its repressed and active states, while both calmodulin and calcineurin are activated by GnRH (reference 49 and this study). Given that calcineurin appears to have a crucial role in GnRH-induced transcription of both the Nur77 and FSHß genes, we consider this a probable mechanism for GnRH-stimulated MEF2 activation of both genes.
Less has been documented about the ability of Nur77 to act as a repressor of transcription, but it is reported to interact with SMRT, and this can be regulated by CaMKIV (53). Given that Nur77, which is present only at low levels in unstimulated immature gonadotrope cells, is also found at the FSHß gene promoter before and after GnRH treatment, we considered that it, too, might convert to an activator after the hormonal treatment. The marked increase in the ratio of total Nur77 to pNur77, which occurred after GnRH exposure, indicated that dephosphorylation may activate Nur77, and this was corroborated by overexpression of Nur77 mutants showing that pNur77 is unable to derepress the FSHß gene. This is reminiscent of the situation in YI adrenocortical cells in which adrenocorticotrope hormone was noted to stimulate Nur77 activity through its dephosphorylation at S354, although the phosphatase was not identified (33).
Previous reports have indicated that phosphorylation of Nur77 at S354, which is at the C-terminal end of the DNA binding domain, may lead to its reduced affinity for DNA (7), although in the present study it clearly was associated with the FSHß gene promoter, possibly facilitated by protein-protein interactions with other DNA-bound factors. Notably, according to the gene context, Nur77 can bind the DNA as a monomer or a heterodimer together with other members of this family of transcription factors (e.g., Nurr1 and NOR1) or with retinoid X receptor (RXR) (60). Interaction with RXR involves the DNA binding domains of both proteins unless the RXR ligand is present, which causes a switch of the dimerization interface to the ligand binding domain (3). Clearly, interaction of Nur77 with coactivators and corepressors involves both N-terminal AF-1 and C-terminal AF-2 domains, and we can currently only hypothesize that phosphorylation at S354 might induce a conformational change to alter some of these interactions; this is currently an area of our ongoing study (3, 36, 53, 60).
Taking these results together, we propose that GnRH derepresses the FSHß gene in the immature gonadotrope by targeting both Nur77 and FSHß genes, involving the following: (i) CaMKI phosphorylation of class IIa HDACs associated with both Nur77 and FSHß gene promoters, causing disruption of the repressive complexes and their nuclear export, possibly involving also calmodulin competing with MEF2D for HDAC4 (65); (ii) GnRH activation of calcineurin, leading to the stimulation of Nur77 gene expression (presumably involving NFAT as has been shown in T cells [66]) and also likely dephosphorylation of Nur77; (iii) the dephosphorylated Nur77 then activates the FSHß gene by facilitating the recruitment of coactivators and additional transcription factors recruited as a result of activation of the other GnRH signaling pathways (Fig. 9).
![]() View larger version (37K): [in a new window] |
FIG. 9. A model depicting the proposed mechanisms through which GnRH derepresses the FSHß gene in immature gonadotropes. (A) GnRH binds to its G-protein-coupled receptor resulting in Ca2+ influx and activation of calmodulin. The calmodulin activates CaMKI, which phosphorylates class IIa HDACs at the FSHß and Nur77 gene promoters, causing their dissociation from the complex and nuclear export, likely as a result of their binding 14-3-3 proteins. This may be helped by calmodulin's competing with MEF2D for binding HDAC4, both of which are associated with both promoters. (B) The activation of calmodulin by GnRH also leads to an increase in calcineurin levels, which stimulates Nur77 expression, likely as has been shown in T cells, through dephosphorylation of NFAT, which allows NFAT to translocate into the nucleus and activate Nur77 gene transcription. At the same time, calcineurin likely activates Nur77 through its dephosphorylation. (C) The increase in active nonphosphorylated Nur77 then activates the FSHß gene by facilitating the recruitment of coactivators, possibly together with MEF2D and additional transcription factors (speckled ovals) recruited as a result of activation of other GnRH signaling pathways.
|
This work was supported by grants from the Academic Research Fund, National University of Singapore. S.L. is an A*STAR graduate scholar, M.K. is a recipient of a Singapore Millennium Foundation scholarship, and P.M. is a recipient of the Young Investigator Award, Office of Life Sciences, National University of Singapore.
Published ahead of print on 19 March 2007. ![]()
S.L., M.L., and M.K. contributed equally to this work. ![]()
|
|
|---|
B in I
B
gene promoter. J. Biol. Chem. 280:21091-21098.
directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115:751-763.[CrossRef][Medline]This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»